At a glance
ClinicalIndex Comparison Record- ✓Age 50 years or older
- ✕Prior history of herpes zoster (shingles)
- ✕Prior receipt of varicella or zoster vaccine
- ✕Immunosuppressed status
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blind, Randomized, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of V211 Administered Concomitantly Versus Nonconcomitantly With Influenza Virus Vaccine (Inactivated)
In Brief
A Phase 3 clinical trial evaluating ZOSTAVAX™ (concomitant), Comparator: Influenza Vaccine, and 1 other intervention for Herpes Zoster. Completed, enrolled 763 participants.
Detailed Summary
The purpose of this study is to determine whether the investigational zoster vaccine has a comparable immune response (the body's ability to protect against disease) and safety profile when given concomitantly with another vaccine.
Study Details
Timeline
Interventions
a single administration of 0.65 mL subcutaneous injection of zoster vaccine live on Day 1 and placebo at Week 4
a single administration of 0.5 mL intramuscular injection of influenza vaccine (inactivated) at Day 1
Placebo injection on Day 1 and a single administration of 0.65 mL subcutaneous injection of zoster vaccine live at Week 4